Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of MB09 vs Prolia in Postmenopausal Osteoporosis
NCT05338086Phase 3Completed
- Sponsor
- mAbxience
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of DenOsteoRel in postmenopausal osteoporosis, sponsored by mAbxience. Started Mar 2022; status: completed.
02
Drugs
DenOsteoRel
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT05338086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338086.